ImmunityBio Stock Pre-Market (+9.4%): Strong Anktiva Revenue & Positive Trial Data

IBRX – a biotechnology company developing cancer-treating immunotherapies and vaccines- is surging after a series of major positive updates, including blowout preliminary 2025 revenue for its cancer therapy Anktiva and an accelerated timeline for its bladder cancer trial. The sentiment is clearly bullish, but after a strong multi-day run, can the stock absorb profit-taking and hold the gap?

This is a structural catalyst. The news transforms the narrative from a clinical-stage biotech to a commercial growth story, validating Anktiva’s market adoption and expanding its future potential.

• Anktiva 2025 preliminary net revenue hit $113 million, a ~700% year-over-year increase.
• Positive interim data from its bladder cancer trial showed prolonged patient response.
• Enrollment for the new trial is >85% complete, accelerating the timeline for a BLA filing to year-end 2026.

But here is the interesting part. You are reading about this 9.4% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio has flagged 5 new opportunities that have not surged yet.

Playbook On Market Open

The session will be a battle between fresh buyers reacting to fundamental improvements and traders taking profits on the multi-day rally. Watch volume for confirmation.

• BULL CASE (Gap & Go): Volume remains high as the price consolidates above the pre-market highs.
• BEAR CASE (Gap & Fade): The stock opens strong but fails to hold opening levels. A break below the prior day’s high would signal a reversal.
• A broad market sell-off could also trigger profit-taking and negate the catalyst’s initial strength.

Verdict

CONDITIONAL VERDICT: If price holds above $4.15, this is a BUY THE OPEN scenario, confirming bullish momentum. If it breaks below $4.15, it becomes a FADE THE GAP opportunity as early buyers turn sellers. The catalyst is fundamentally strong, but the recent run makes the entry tricky, with the pivot separating breakout from fade.
Understanding price behavior can give you an edge. See more.

Want to make sure you never miss the explainer on IBRX’s next move? Stay updated with Upcoming Events and Latest Analyses

That’s for now, but so much more goes into evaluating a stock from long-term investment perspective. We make it easy with our Investment Highlights

The Best Investors Think In Portfolios

Individual stocks are unpredictable. A smart portfolio keeps you invested, limits downside shocks, and provides upside exposure

The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.